Erica Schwartz CDC nomination hearing
Analysis based on 10 articles · First reported Jul 15, 2026 · Last updated Jul 15, 2026
The nomination of a new CDC director could stabilize the agency's leadership, potentially restoring some confidence in public health guidance. However, ongoing political interference and workforce losses may continue to undermine the CDC's effectiveness, affecting healthcare and pharmaceutical sectors reliant on CDC recommendations.
Dr. Erica Schwartz, a former U.S. Coast Guard leader and deputy surgeon general, appeared before a U.S. Senate committee on Wednesday for her nomination to become director of the United States — Centers for Disease Control and Prevention (CDC). The CDC has been in turmoil since President Donald Trump returned to office, losing over 3,000 employees due to layoffs and resignations, with morale plummeting amid a revolving door of temporary leaders. The agency is overseen by Health Secretary Robert F. Kennedy Jr., who has attempted to rewrite childhood vaccine recommendations, some efforts blocked by a federal judge. Schwartz, if confirmed, will leave her position at UnitedHealth Group and resign from boards of Butterfly Network, Aveanna Healthcare, and Searching for Solutions Institute. Also at the hearing, the Senate considered Sean Kaufman's nomination as Assistant Secretary for Preparedness and Response.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard